Koper

Researchers are evaluating the real-world effectiveness of a fixed triple inhaled combination therapy called Trimbow 17259 g pMDI in adults with asthma. This study focuses on patients with severe asthma who have been treated for at least three years but still have uncontrolled symptoms despite using other inhaled therapies. The research aims to assess improvements in asthma symptom scores over six months after switching to Trimbow, as well as treatment adherence and lung function. The study is a multicenter, national, prospective, non-interventional design where patients are observed after their doctors independently decide to switch their inhaled therapy to Trimbow 17259 g pMDI. The recommended dose is two inhalations twice daily. Participants will be followed for six months, with assessments at enrollment, one month, and six months. If their asthma treatment changes away from Trimbow during the study, they are excluded. Other asthma medications and reliever inhalers are allowed as usual. Participants will attend three visits during routine clinical care where researchers will collect information on demographics, medical history, asthma control test ACT scores, lung function if available, medication adherence using a questionnaire, and any changes in asthma treatment. The main measure is the change in ACT score over six months. Secondary measures include lung function improvement and adherence to treatment. Safety and treatment changes are monitored throughout the study, which is expected to run from November 2024 to June 2026.

Researchers are evaluating how continuous glucose monitoring CGM affects blood sugar fluctuations, lifestyle habits, and metabolic health in adults with prediabetes who are overweight or obese BMI of 27 kgm or higher. The study aims to find out if having real-time access to glucose data encourages behavior changes and improves metabolic outcomes compared to using CGM without seeing the glucose data. This randomized, open-label crossover study involves 30 adults aged 18 to 70 years with confirmed prediabetes and stable weight. Participants will undergo two 12-week phases using a CGM device one with real-time glucose data visible open CGM and one with glucose data hidden blinded CGM. The order of these phases is randomized and separated by a 30-day washout period. During the open CGM phase, participants can view their glucose levels continuously, while in the blinded phase, the data is masked. The study evaluates how access to glucose information influences diet, physical activity, and metabolic markers. Throughout the study, participants will attend baseline and follow-up visits where their weight, blood tests, physical activity, dietary intake, and health status are assessed. The primary outcomes include changes in glycemic variability and daily energy intake measured at the end of each 12-week CGM phase. Secondary measures include changes in body weight, blood glucose levels, HbA1c, physical activity, and participant adherence to CGM use. The total study duration for each participant includes the two 12-week CGM phases plus the washout period.